AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36639249 — intervention group
Group type: EXPERIMENTAL
Intervention: diazoxide choline extended-release tablet (DCCR)
Number of subjects: 127
Study 36639249 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 127
Study 36639329 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250mg b.i.d for 5 weeks)
Number of subjects: 28
Study 36639329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 36639329 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 28
Study 36639540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of rectus femoris cross-sectional area (RFcsa) on days 1 and 7 of ICU stay
Number of subjects: 104
Study 36639540 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 104
Study 36639540 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day mortality rate
Number of subjects: 104
Study 36639565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stress protocol (20-min alternating relaxation and cognitive stress)
Number of subjects: 82
Study 36639565 — intervention group
Group type: COMPARATOR
Intervention: Healthy female controls
Number of subjects: 82
Study 36639624 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation after surgery
Number of subjects: 1771
Study 36639624 — intervention group
Group type: COMPARATOR
Intervention: Discharge directly home
Number of subjects: 1771
Study 36639636 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades 3-4 hyperbilirubinemia during induction/consolidation treatment
Number of subjects: 1547
Study 36639636 — intervention group
Group type: COMPARATOR
Intervention: Grades 1-2 hyperbilirubinemia during induction/consolidation treatment
Number of subjects: 1547
Study 36639636 — intervention group
Group type: COMPARATOR
Intervention: Grade 0 hyperbilirubinemia during induction/consolidation treatment
Number of subjects: 1547
Study 36639798 — intervention group
Group type: EXPERIMENTAL
Intervention: early-PN
Number of subjects: 818
Study 36639798 — intervention group
Group type: EXPERIMENTAL
Intervention: late-PN
Number of subjects: 818
Study 36639798 — intervention group
Group type: COMPARATOR
Intervention: healthy children
Number of subjects: 818
Study 36639814 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical cystectomy (RARC) with intracorporeal ileal conduit diversion
Number of subjects: 50
Study 36639814 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC) with ileal conduit
Number of subjects: 50
Study 36639814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RARC and ORC
Number of subjects: 50
Study 36640127 — intervention group
Group type: EXPERIMENTAL
Intervention: MDNA55 (interleukin 4 receptor-targeting toxin) administered intratumorally as a single dose treatment (dose range of 18 to 240 μg) using convection-enhanced delivery (CED).
Number of subjects: 44
Study 36640127 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MDNA55 (>180 μg) in a subgroup of IL4R High and IL4R Low patients.
Number of subjects: 44
Study 36640127 — intervention group
Group type: EXPERIMENTAL
Intervention: MDNA55 treatment in evaluable patients (n=32) based on mRANO criteria.
Number of subjects: 44
Study 36640137 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS-IL12 12 µg/kg SC q2w
Number of subjects: 13
Study 36640137 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS-IL12 16.8 µg/kg SC q2w
Number of subjects: 13
Study 36640164 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic urinary continence assessment system
Number of subjects: 101
Study 36640164 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study 36640164 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 36640430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (CRYO)
Number of subjects: 98
Study 36640430 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF)
Number of subjects: 98
Study 36640437 — intervention group
Group type: EXPERIMENTAL
Intervention: Realwear HMT-1 assisted reality device
Number of subjects: 139
Study 36640582 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and magnesium supplementation (1000 IU vitamin D)
Number of subjects: 78
Study 36640582 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation alone
Number of subjects: 78
Study 36640582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 36640725 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg AVA treatment
Number of subjects: 0
Study 36640725 — intervention group
Group type: COMPARATOR
Intervention: 30 mg AVA
Number of subjects: 0
Study 36640725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36640790 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 278
Study 36640790 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided hemicolectomy
Number of subjects: 278
Study 36640794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (infliximab + immunosuppressant)
Number of subjects: 207
Study 36640794 — intervention group
Group type: COMPARATOR
Intervention: Infliximab withdrawal
Number of subjects: 207
Study 36640794 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressant withdrawal
Number of subjects: 207
Study 36640860 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert notifying cardiologists at the time of patient visit
Number of subjects: 596
Study 36640860 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated electronic message allowing review between visits
Number of subjects: 596
Study 36640860 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 596
Study 36640862 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment device (including daily bidirectional text messages, commitment contract, implementation intentions, support partner involvement)
Number of subjects: 37
Study 36640862 — intervention group
Group type: COMPARATOR
Intervention: Attention control (daily bidirectional text messages asking about adherence and weekly messages for weight and blood pressure)
Number of subjects: 37
Study 36640965 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (when both FFR ≤ 0.80 and CFR < 2.0 were abnormal)
Number of subjects: 348
Study 36640965 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (for all others not undergoing revascularization)
Number of subjects: 348
Study 36640965 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordantly normal FFR/CFR
Number of subjects: 348
Study 36641027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog treatment (DT)
Number of subjects: 128
Study 36641027 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 128
Study 36641093 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleclumab 1500 mg (DL1) plus osimertinib 80 mg
Number of subjects: 26
Study 36641093 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleclumab 3000 mg (DL2) plus osimertinib 80 mg
Number of subjects: 26
Study 36641341 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3/AS01
Number of subjects: 40
Study 36641341 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 36641358 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccination (FV)
Number of subjects: 4307
Study 36641358 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal vaccination (PV)
Number of subjects: 4307
Study 36641457 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain language recommendation (PLR) format
Number of subjects: 240
Study 36641457 — intervention group
Group type: COMPARATOR
Intervention: Standard language version (original recommendation format)
Number of subjects: 240
Study 36641605 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
Number of subjects: 769
Study 36641605 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
Number of subjects: 769
Study 36641605 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Deterioration Scale and MCI-Clinical Global Impression of Change (anchor measures)
Number of subjects: 769
Study 36641607 — intervention group
Group type: COMPARATOR
Intervention: 80mg buntanetap QD in AD patients
Number of subjects: 68
Study 36641607 — intervention group
Group type: COMPARATOR
Intervention: 5mg, 10mg, 20mg, 40mg, 80mg buntanetap QD in PD patients
Number of subjects: 68
Study 36641607 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD in AD patients
Number of subjects: 68
Study 36641607 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD in PD patients
Number of subjects: 68
Study 36641609 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and Cued Selective Reminding Test (FCSRT)
Number of subjects: 2897
Study 36641609 — intervention group
Group type: COMPARATOR
Intervention: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Number of subjects: 2897
Study 36641609 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating-Sum of Boxes (CDR-SB)
Number of subjects: 2897
Study 36641609 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13)
Number of subjects: 2897
Study 36641609 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL)
Number of subjects: 2897
Study 36641898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 455
Study 36641898 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 455
Study 36641898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lapatinib and trastuzumab
Number of subjects: 455
Study 36641898 — intervention group
Group type: COMPARATOR
Intervention: pCR (pathological complete response)
Number of subjects: 455
Study 36642080 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone
Number of subjects: 180
Study 36642080 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide alone
Number of subjects: 180
Study 36642225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting balloon (SEB) and provisional drug-eluting stent (DES)
Number of subjects: 3326
Study 36642225 — intervention group
Group type: COMPARATOR
Intervention: Systematic drug-eluting stent (DES)
Number of subjects: 3326
Study 36642226 — intervention group
Group type: EXPERIMENTAL
Intervention: Core digital engagement program (CDEP) via iPhone application and Apple Watch (Apple Watch Group)
Number of subjects: 26485
Study 36642226 — intervention group
Group type: COMPARATOR
Intervention: Core digital engagement program (CDEP) alone (iPhone-only Group)
Number of subjects: 26485
Study 36642226 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch Group
Number of subjects: 26485
Study 36642232 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM-guided voriconazole treatment
Number of subjects: 189
Study 36642232 — intervention group
Group type: COMPARATOR
Intervention: Standard voriconazole dosing
Number of subjects: 189
Study 36642232 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite primary endpoint (TDM group)
Number of subjects: 189
Study 36642366 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (250 mg/d escalated to 1,000 mg/d over 24 weeks)
Number of subjects: 25
Study 36642366 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (combined with sirolimus)
Number of subjects: 25
Study 36642366 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus alone (control)
Number of subjects: 25
Study 36642439 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (GUS) 100 mg every 4 weeks (Q4W)
Number of subjects: 1554
Study 36642439 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (GUS) 100 mg every 8 weeks (Q8W)
Number of subjects: 1554
Study 36642439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GUS (Q4W + Q8W)
Number of subjects: 1554
Study 36642439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1554
Study 36642509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 164
Study 36642509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 36642608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 30
Study 36642608 — intervention group
Group type: COMPARATOR
Intervention: lacto-ovo-vegetarian diet (VD)
Number of subjects: 30
Study 36642608 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCA1 transporter
Number of subjects: 30
Study 36642667 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (0.107 mg/kg, 8 mg for a 75-kg person)
Number of subjects: 47
Study 36642667 — intervention group
Group type: EXPERIMENTAL
Intervention: THC+CBD (0.107 mg/kg THC + 0.320 mg/kg CBD, 24 mg for a 75-kg person)
Number of subjects: 47
Study 36642667 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 47
Study 36642931 — intervention group
Group type: EXPERIMENTAL
Intervention: NP10679, single or multiple doses
Number of subjects: 0
Study 36643406 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal palpation tests
Number of subjects: 44
Study 36643406 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior wall structure palpation (firm/soft)
Number of subjects: 44
Study 36643406 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior wall bulging test (yes/no)
Number of subjects: 44
Study 36643406 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal resistance tests
Number of subjects: 44
Study 36643406 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation during scrotal invagination with Valsalva manoeuvre
Number of subjects: 44
Study 36643597 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions with school-based health center (SBHC) primary care clinicians over two years
Number of subjects: 0
Study 36643597 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions
Number of subjects: 0
Study 36643727 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia in T2D
Number of subjects: 46
Study 36643727 — intervention group
Group type: COMPARATOR
Intervention: Insulin-induced hypoglycemia in controls
Number of subjects: 46
Study 36643855 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination (two doses at 3-week intervals)
Number of subjects: 100
Study 36643855 — intervention group
Group type: COMPARATOR
Intervention: Home-isolated COVID-19 patients (control group)
Number of subjects: 100
Study 36644169 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPP-Kit PNX with resorbable bio-compatible glue
Number of subjects: 40
Study 36644285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Number of subjects: 0
Study 36644285 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36644348 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0
Study 36644348 — intervention group
Group type: COMPARATOR
Intervention: CNI-based regimen (Control)
Number of subjects: 0
Study 36644504 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Systolic Velocity (PSV) in Common Carotid Artery (CCA)
Number of subjects: 8567
Study 36644504 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Systolic Velocity (PSV) in Internal Carotid Artery (ICA)
Number of subjects: 8567
Study 36644605 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-time reduction to ≤1 screen-hour daily
Number of subjects: 49
Study 36644605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CVS diagnosis)
Number of subjects: 49
Study 36644672 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally informed stress reduction intervention for Native American Head Start teachers
Number of subjects: 0
Study 36644804 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG + CAF
Number of subjects: 21
Study 36644804 — intervention group
Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 21
Study 36644815 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin facial bone (≤1 mm)
Number of subjects: 42
Study 36644815 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 42
Study 36644853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0
Study 36644853 — intervention group
Group type: COMPARATOR
Intervention: Imatinib mesylate
Number of subjects: 0
Study 36644853 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib and regorafenib
Number of subjects: 0
Study 36645051 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 45 mg once daily for 8 weeks (induction)
Number of subjects: 0
Study 36645051 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 15 mg or 30 mg once daily for 52 weeks (maintenance)
Number of subjects: 0
Study 36645051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36645168 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg BID) administered concurrent with chemotherapy
Number of subjects: 56
Study 36645227 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention targeting physical weakness, cognitive impairment, malnutrition, and anemia
Number of subjects: 142
Study 36645227 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study 36645250 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 1295
Study 36645250 — intervention group
Group type: COMPARATOR
Intervention: No remote ischaemic preconditioning (no RIPC)
Number of subjects: 1295
Study 36645291 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (reduced salt intake)
Number of subjects: 313
Study 36645446 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (daily telemedical rounds guided by eight German acute ICU care QIs)
Number of subjects: 1463
Study 36645446 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 1463
Study 36645446 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 1463
Study 36645499 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress screeners (DT, PHQ-9, GAD-7)
Number of subjects: 660
Study 36645499 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 and GAD-7
Number of subjects: 660
Study 36645499 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress screeners
Number of subjects: 660
Study 36645531 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC-IN score ≥ 4
Number of subjects: 4707
Study 36645531 — intervention group
Group type: COMPARATOR
Intervention: CVC-IN score < 4
Number of subjects: 4707
Study 36645531 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC-IN score
Number of subjects: 4707
Study 36645699 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Parenting App (SPA) intervention
Number of subjects: 400
Study 36645699 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 36645708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomando Control educational program delivered in a group format for 6 biweekly 1.5-hour sessions, led by either a community health worker or a diabetes nurse educator.
Number of subjects: 330
Study 36645708 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented version of Tomando Control or multifamily group treatment focused on problem-solving (for those who did not improve in the first phase).
Number of subjects: 330
Study 36645792 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary dolutegravir (50 mg) for 14 days
Number of subjects: 130
Study 36645792 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 130
Study 36645792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (supplementary dolutegravir and placebo)
Number of subjects: 130
Study 36645791 — intervention group
Group type: EXPERIMENTAL
Intervention: HICs
Number of subjects: 12860
Study 36645791 — intervention group
Group type: COMPARATOR
Intervention: LMICs
Number of subjects: 12860
Study 36645791 — intervention group
Group type: COMPARATOR
Intervention: Mechanically ventilated children in LMICs
Number of subjects: 12860
Study 36645885 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP (dieting group)
Number of subjects: 43
Study 36645885 — intervention group
Group type: COMPARATOR
Intervention: CTRL (nondieting group)
Number of subjects: 43
Study 36645965 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined optokinetic stimulation and cueing-assisted reading therapy (OKSREAD)
Number of subjects: 20
Study 36645965 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (neuropsychological treatment not targeting visuospatial attention)
Number of subjects: 20
Study 36645978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA)
Number of subjects: 69
Study 36645978 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 69
Study 36646148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stents (LAMSs) with coaxial double-pigtail plastic stents (DPSs)
Number of subjects: 67
Study 36646148 — intervention group
Group type: COMPARATOR
Intervention: Lumen-apposing metal stents (LAMSs) without coaxial double-pigtail plastic stents (DPSs)
Number of subjects: 67
Study 36646196 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily
Number of subjects: 27395
Study 36646196 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily alone
Number of subjects: 27395
Study 36646196 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg daily
Number of subjects: 27395
Study 36646196 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban with aspirin
Number of subjects: 27395
Study 36646210 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus carboplatin and pemetrexed
Number of subjects: 412
Study 36646210 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 412
Study 36646240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab injections (7 monthly doses followed by PRN)
Number of subjects: 95